Diabetes evolution in rats after neonatal treatment with alloxan

Detalhes bibliográficos
Autor(a) principal: Ribeiro, Carla [UNESP]
Data de Publicação: 2005
Outros Autores: De Oliveira, Camila Aparecida Machado [UNESP], Luciano, Eliete [UNESP], De Mello, Maria Alice Rostom [UNESP]
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNESP
Texto Completo: http://hdl.handle.net/11449/225062
Resumo: Physical exercises have been recommended in the prevention of non-insulin dependent diabetes mellitus (NIDDM), but the mechanisms involved in this intervention are not yet fully understood. Experimental models offer the opportunity for the study of this matter. The present study was designed to analyze the diabetes evolution in rats submitted to neonatal treatment with alloxan with the objective of verifying the suitability of the model to future studies with exercises. For this, newly born rats (6 days old) received intraperitoneal alloxan (A= 200 mg/kg of body weight). Rats injected with vehicle (citrate buffer) were used as controls (C). The fasting blood glucose level (mg/dL) was higher in the alloxan group at the day 28 (C=47.25 ± 5.08; A=54.51 ± 7.03) but not at the 60 day of age (C=69.18 ± 8.31; A=66.81 ± 6.08). The alloxan group presented higher blood glucose level during glucose tolerance test (GTT) (mg/dL. 120 min) in relation to the control group both at day 28 (C=16908.9 ± 1078.8; A=21737,7 ± 1106.4) and at day 60 (C=11463.45 ± 655.30; A=15282.21 ± 1221.84). Insulinaemia during GTT (ng/mL.120 min) was lower at day 28 (C=158.67 ± 33.34; A=123.90 ± 19.80), but presented no difference at day 60 (C=118.83 ± 26.02; A=97.88 ± 10.88). At day 60, the glycogen concentration in the soleus muscle (mg/100mg) was lower in the alloxan group (0.3 ± 0.13) in relation to the control group (0.5 ± 0.07). No difference was observed between groups in relation to (μmol/g.h): Glucose Uptake (C= 5.8 ± 0.63; A= 5.2 ± 0.73); Glucose Oxidation (C= 4.3 ± 1.13; A= 3.9± 0.44); Glycogen Synthesis (C= 0.8± 0.18; A= 0.7 ± 0.18) and Lactate Production (C= 3.8± 0.8; A= 3.8± 0.7) by the isolated soleus muscle. The glucose-stimulated insulin secretion (16.7mM) by the isolated islets (ng/5 islets, h) of the alloxan group was lower (14.3± 4.7) than the control group (32.0± 7.9). Thus, we may conclude that this neonatal diabetes induction model gathers interesting characteristics and may be useful for further studies on the role of the exercise in the diabetes mellitus appearance. Copyright © 2005 by PJD Publications Limited.
id UNSP_806fb8ab9a00af9731479e682f77ae88
oai_identifier_str oai:repositorio.unesp.br:11449/225062
network_acronym_str UNSP
network_name_str Repositório Institucional da UNESP
repository_id_str 2946
spelling Diabetes evolution in rats after neonatal treatment with alloxanAlloxanDiabetes mellitusNeonatal treatmentRatsPhysical exercises have been recommended in the prevention of non-insulin dependent diabetes mellitus (NIDDM), but the mechanisms involved in this intervention are not yet fully understood. Experimental models offer the opportunity for the study of this matter. The present study was designed to analyze the diabetes evolution in rats submitted to neonatal treatment with alloxan with the objective of verifying the suitability of the model to future studies with exercises. For this, newly born rats (6 days old) received intraperitoneal alloxan (A= 200 mg/kg of body weight). Rats injected with vehicle (citrate buffer) were used as controls (C). The fasting blood glucose level (mg/dL) was higher in the alloxan group at the day 28 (C=47.25 ± 5.08; A=54.51 ± 7.03) but not at the 60 day of age (C=69.18 ± 8.31; A=66.81 ± 6.08). The alloxan group presented higher blood glucose level during glucose tolerance test (GTT) (mg/dL. 120 min) in relation to the control group both at day 28 (C=16908.9 ± 1078.8; A=21737,7 ± 1106.4) and at day 60 (C=11463.45 ± 655.30; A=15282.21 ± 1221.84). Insulinaemia during GTT (ng/mL.120 min) was lower at day 28 (C=158.67 ± 33.34; A=123.90 ± 19.80), but presented no difference at day 60 (C=118.83 ± 26.02; A=97.88 ± 10.88). At day 60, the glycogen concentration in the soleus muscle (mg/100mg) was lower in the alloxan group (0.3 ± 0.13) in relation to the control group (0.5 ± 0.07). No difference was observed between groups in relation to (μmol/g.h): Glucose Uptake (C= 5.8 ± 0.63; A= 5.2 ± 0.73); Glucose Oxidation (C= 4.3 ± 1.13; A= 3.9± 0.44); Glycogen Synthesis (C= 0.8± 0.18; A= 0.7 ± 0.18) and Lactate Production (C= 3.8± 0.8; A= 3.8± 0.7) by the isolated soleus muscle. The glucose-stimulated insulin secretion (16.7mM) by the isolated islets (ng/5 islets, h) of the alloxan group was lower (14.3± 4.7) than the control group (32.0± 7.9). Thus, we may conclude that this neonatal diabetes induction model gathers interesting characteristics and may be useful for further studies on the role of the exercise in the diabetes mellitus appearance. Copyright © 2005 by PJD Publications Limited.Department of Physical Education IB UNESP, Rio Claro, SPDepartamento de Educação Física IB UNESP, Av. 24 A, 1515, 13506-900 Rio Claro, SPDepartment of Physical Education IB UNESP, Rio Claro, SPDepartamento de Educação Física IB UNESP, Av. 24 A, 1515, 13506-900 Rio Claro, SPUniversidade Estadual Paulista (UNESP)Ribeiro, Carla [UNESP]De Oliveira, Camila Aparecida Machado [UNESP]Luciano, Eliete [UNESP]De Mello, Maria Alice Rostom [UNESP]2022-04-28T20:37:19Z2022-04-28T20:37:19Z2005-12-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article29-46Research Communications in Molecular Pathology and Pharmacology, v. 117-118, p. 29-46.1078-0297http://hdl.handle.net/11449/2250622-s2.0-40549117485Scopusreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengResearch Communications in Molecular Pathology and Pharmacologyinfo:eu-repo/semantics/openAccess2022-04-28T20:37:19Zoai:repositorio.unesp.br:11449/225062Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462022-04-28T20:37:19Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false
dc.title.none.fl_str_mv Diabetes evolution in rats after neonatal treatment with alloxan
title Diabetes evolution in rats after neonatal treatment with alloxan
spellingShingle Diabetes evolution in rats after neonatal treatment with alloxan
Ribeiro, Carla [UNESP]
Alloxan
Diabetes mellitus
Neonatal treatment
Rats
title_short Diabetes evolution in rats after neonatal treatment with alloxan
title_full Diabetes evolution in rats after neonatal treatment with alloxan
title_fullStr Diabetes evolution in rats after neonatal treatment with alloxan
title_full_unstemmed Diabetes evolution in rats after neonatal treatment with alloxan
title_sort Diabetes evolution in rats after neonatal treatment with alloxan
author Ribeiro, Carla [UNESP]
author_facet Ribeiro, Carla [UNESP]
De Oliveira, Camila Aparecida Machado [UNESP]
Luciano, Eliete [UNESP]
De Mello, Maria Alice Rostom [UNESP]
author_role author
author2 De Oliveira, Camila Aparecida Machado [UNESP]
Luciano, Eliete [UNESP]
De Mello, Maria Alice Rostom [UNESP]
author2_role author
author
author
dc.contributor.none.fl_str_mv Universidade Estadual Paulista (UNESP)
dc.contributor.author.fl_str_mv Ribeiro, Carla [UNESP]
De Oliveira, Camila Aparecida Machado [UNESP]
Luciano, Eliete [UNESP]
De Mello, Maria Alice Rostom [UNESP]
dc.subject.por.fl_str_mv Alloxan
Diabetes mellitus
Neonatal treatment
Rats
topic Alloxan
Diabetes mellitus
Neonatal treatment
Rats
description Physical exercises have been recommended in the prevention of non-insulin dependent diabetes mellitus (NIDDM), but the mechanisms involved in this intervention are not yet fully understood. Experimental models offer the opportunity for the study of this matter. The present study was designed to analyze the diabetes evolution in rats submitted to neonatal treatment with alloxan with the objective of verifying the suitability of the model to future studies with exercises. For this, newly born rats (6 days old) received intraperitoneal alloxan (A= 200 mg/kg of body weight). Rats injected with vehicle (citrate buffer) were used as controls (C). The fasting blood glucose level (mg/dL) was higher in the alloxan group at the day 28 (C=47.25 ± 5.08; A=54.51 ± 7.03) but not at the 60 day of age (C=69.18 ± 8.31; A=66.81 ± 6.08). The alloxan group presented higher blood glucose level during glucose tolerance test (GTT) (mg/dL. 120 min) in relation to the control group both at day 28 (C=16908.9 ± 1078.8; A=21737,7 ± 1106.4) and at day 60 (C=11463.45 ± 655.30; A=15282.21 ± 1221.84). Insulinaemia during GTT (ng/mL.120 min) was lower at day 28 (C=158.67 ± 33.34; A=123.90 ± 19.80), but presented no difference at day 60 (C=118.83 ± 26.02; A=97.88 ± 10.88). At day 60, the glycogen concentration in the soleus muscle (mg/100mg) was lower in the alloxan group (0.3 ± 0.13) in relation to the control group (0.5 ± 0.07). No difference was observed between groups in relation to (μmol/g.h): Glucose Uptake (C= 5.8 ± 0.63; A= 5.2 ± 0.73); Glucose Oxidation (C= 4.3 ± 1.13; A= 3.9± 0.44); Glycogen Synthesis (C= 0.8± 0.18; A= 0.7 ± 0.18) and Lactate Production (C= 3.8± 0.8; A= 3.8± 0.7) by the isolated soleus muscle. The glucose-stimulated insulin secretion (16.7mM) by the isolated islets (ng/5 islets, h) of the alloxan group was lower (14.3± 4.7) than the control group (32.0± 7.9). Thus, we may conclude that this neonatal diabetes induction model gathers interesting characteristics and may be useful for further studies on the role of the exercise in the diabetes mellitus appearance. Copyright © 2005 by PJD Publications Limited.
publishDate 2005
dc.date.none.fl_str_mv 2005-12-01
2022-04-28T20:37:19Z
2022-04-28T20:37:19Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv Research Communications in Molecular Pathology and Pharmacology, v. 117-118, p. 29-46.
1078-0297
http://hdl.handle.net/11449/225062
2-s2.0-40549117485
identifier_str_mv Research Communications in Molecular Pathology and Pharmacology, v. 117-118, p. 29-46.
1078-0297
2-s2.0-40549117485
url http://hdl.handle.net/11449/225062
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Research Communications in Molecular Pathology and Pharmacology
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 29-46
dc.source.none.fl_str_mv Scopus
reponame:Repositório Institucional da UNESP
instname:Universidade Estadual Paulista (UNESP)
instacron:UNESP
instname_str Universidade Estadual Paulista (UNESP)
instacron_str UNESP
institution UNESP
reponame_str Repositório Institucional da UNESP
collection Repositório Institucional da UNESP
repository.name.fl_str_mv Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)
repository.mail.fl_str_mv
_version_ 1799964636668231680